(PDF) The Silence in Hoch Et Al.’s Commentary About the

The Silence in Hoch Et Al.’s Commentary About the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability When Allocating Taxpayers’ Dollars

PharmacoEconomics - United Kingdom

doi 10.1007/s40273-015-0297-4

Full Text

Open PDF

Abstract

Available in full text

Date

June 7, 2015

Authors

Publisher

Springer Science and Business Media LLC

Related search

The Need for Accountability and Transparency in Intercollegiate Athletic Medicine

Journal of Athletic Training

English

Commentary on Stam Et Al . (2019): Drugs, Death and Statistics

English

Commentary on Burgard Et Al . (2019): Wastewater Based Estimates of the Size of Illicit Markets for Psychoactive Drugs

English

Increasing Transparency and the Patient Voice in HTA of New Medicines

English

Psy184 - Hta and Reimbursement Considerations for Rare Diseases in European Markets: What Are the Implications for Manufacturers?s?

English

Capsule Commentary on Weber Et Al.’s Development and Establishment of Initial Validity Evidence for a Novel Tool for Assessing Trainee Admission Notes

Journal of General Internal Medicine

Internal Medicine

2020

English

The Concept(s) of Accountability: Form in Search of Substance

Leiden Journal of International Law

Law

International Relations

Political Science

2016

English

Capsule Commentary on Christian Et Al.’s “Measuring the Health of an Invisible Population: Lessons From the Colorado Transgender Health Survey”

Journal of General Internal Medicine

Internal Medicine

2018

English

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases

English

Amanote Research

The Silence in Hoch Et Al.’s Commentary About the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability When Allocating Taxpayers’ Dollars

PharmacoEconomics - United Kingdom

doi 10.1007/s40273-015-0297-4

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

The Need for Accountability and Transparency in Intercollegiate Athletic Medicine

Commentary on Stam Et Al . (2019): Drugs, Death and Statistics

Commentary on Burgard Et Al . (2019): Wastewater Based Estimates of the Size of Illicit Markets for Psychoactive Drugs

Increasing Transparency and the Patient Voice in HTA of New Medicines

Psy184 - Hta and Reimbursement Considerations for Rare Diseases in European Markets: What Are the Implications for Manufacturers?s?

Capsule Commentary on Weber Et Al.’s Development and Establishment of Initial Validity Evidence for a Novel Tool for Assessing Trainee Admission Notes

The Concept(s) of Accountability: Form in Search of Substance

Capsule Commentary on Christian Et Al.’s “Measuring the Health of an Invisible Population: Lessons From the Colorado Transgender Health Survey”

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency